SCHEMBL11042318

SCHEMBL11042318

CCOc1ccc(C(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.67
NPSR1 Q6W5P4 1/20 0.67
MAOB P27338 2/20 0.63
PARP10 Q53GL7 1/20 0.59
CHRNA7 P36544 2/20 0.58
LMNA P02545 3/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
NPC1 O15118 2/20 0.56
PLK1 P53350 1/20 0.56
HPGD P15428 3/20 0.55
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 1/20 0.55
MAPT P10636 1/20 0.55
ALOX15 P16050 1/20 0.55
RECQL P46063 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TSHR P16473 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845348 0.90 NPSR1 (0.79) KMT2ANPSR1PARP10LMNAMAPK1
SCHEMBL1547683 0.84 NQO1 (0.74) KMT2AMAOBPARP10L3MBTL1ALDH1A1
SCHEMBL11576081 0.83 KMT2A (0.69) KMT2ANPSR1MAOBPARP10LMNA
SCHEMBL30776959 0.83 KMT2A (0.69) KMT2ANPSR1MAOBPARP10LMNA
Carbamic Acid SCHEMBL11793902 0.83 PARP10 (0.61) KMT2AMAOBPARP10L3MBTL1ALDH1A1
SCHEMBL845256 0.83 L3MBTL1 (0.77) KMT2ANPSR1MAOBPARP10LMNA
Ammonia Solution, Strong SCHEMBL322908 0.82 NQO1 (0.70) KMT2AMAOBPARP10L3MBTL1PLK1
SCHEMBL6655854 0.81 TSHR (0.70) KMT2ANPSR1PARP10LMNAMAPK1
SCHEMBL20496443 0.81 NPSR1 (0.67) KMT2ANPSR1PARP10LMNAMAPK1
SCHEMBL11578668 0.81 KMT2A (0.67) KMT2ANPSR1PARP10LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-08-25 US disclosed
WO-2014205414-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-12-24 WO disclosed
US-4453009-A HALOGEN-FLUORINE EXCHANGE BETWEEN CORRESPONDING 4-HALOGENO- OR 4,4-DIHALOGENOBENZOPHENONE AND ALKALI FLUORIDE MITSUI TOATSU CHEMICALS, INC. (JP) 1984-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS NQO1, TXN2, MPO KMT2A 4713/4885NPSR1 4048/4885MAOB 1961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.